OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Other Long-Term Assets
OSE Immunotherapeutics SA
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Other Long-Term Assets
€194k
|
CAGR 3-Years
6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Long-Term Assets
€17.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Innate Pharma SA
PAR:IPH
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Other Long-Term Assets
€2.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Long-Term Assets
€5.1m
|
CAGR 3-Years
43%
|
CAGR 5-Years
46%
|
CAGR 10-Years
19%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Other Long-Term Assets?
Other Long-Term Assets
194k
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Other Long-Term Assets amounts to 194k EUR.
What is OSE Immunotherapeutics SA's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-7%
Over the last year, the Other Long-Term Assets growth was 5%. The average annual Other Long-Term Assets growth rates for OSE Immunotherapeutics SA have been 6% over the past three years , -7% over the past five years .
You don't have any saved screeners yet